Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Digestive Disorder

PUBLISHER: Grand View Research | PRODUCT CODE: 1726370

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1726370

Non-alcoholic Steatohepatitis Biomarkers Market Size, Share & Trends Analysis Report By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers), By End Use (Pharma & CRO Industry, Hospitals), By Region, And Segment Forecasts, 2025 - 2030

PUBLISHED:
PAGES: 120 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Non-alcoholic Steatohepatitis Biomarkers Market Growth & Trends:

The global non-alcoholic steatohepatitis biomarkers market size is anticipated to reach USD 5.68 billion by 2030 and expand at a CAGR of 23.3% during the forecast period, according to a new report by Grand View Research, Inc. The rising prevalence of Non-alcoholic Steatohepatitis (NASH), fueled by factors such as obesity and diabetes, is significantly driving the demand for NASH biomarkers. The growing diagnosis of NASH drives the demand for accurate diagnostic tools. In addition, government and healthcare initiatives promoting awareness, early detection, and research funding further accelerate market growth. These efforts are crucial in addressing the growing burden of NASH and improving disease management through biomarker development.

Advancements in diagnostic technologies and an increased focus on early detection drive the growth of the NASH biomarkers market. Innovative noninvasive testing methods such as imaging techniques and blood-based biomarkers enable quicker, more accurate diagnoses. Early detection improves treatment outcomes, fueling demand for advanced biomarkers to monitor disease progression. Hence, the growing emphasis of healthcare systems on early intervention impels market growth, helping provide improved solutions for NASH management.

Growing awareness of NASH is expected to propel the demand for effective biomarkers, leading to significant market growth. Increasing recognition of the disease encourages earlier diagnosis and better disease management. Expanding research and development in the field advances the discovery of novel biomarkers, improving diagnostic precision and treatment strategies. These factors are anticipated to drive the demand for NASH biomarkers, contributing to the market expansion.

Non-alcoholic Steatohepatitis Biomarkers Market Report Highlights:

  • On the basis of type, the serum biomarkers segment led the market with the largest revenue share of 31.2% in 2024, attributed to their ability to provide non-invasive, cost-effective, reliable diagnostic options.
  • The hepatic fibrosis biomarkers segment is projected to grow at the fastest CAGR during the forecast period, fueled by their crucial role in assessing the severity and progression of liver damage.
  • On the basis of end use, the pharma & CRO industry segment dominated the market with the largest share in 2024, driven by its critical role in drug development, clinical trials, and biomarker validation.
  • The diagnostic labs segment is set to be the fastest-growing segment from 2025 to 2030 due to increasing awareness and the rising demand for early detection and diagnosis.
  • North America accounted for the largest share of almost 54% in 2024, owing toits advanced healthcare infrastructure, high awareness of liver diseases, and substantial research investments.
Show more
Product Code: GVR-1-68038-518-2

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. End Use
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and Forecasts Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
    • 1.4.5. Details of Primary Research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type Outlook
    • 2.2.2. End Use Outlook
    • 2.2.3. Regional Outlook
  • 2.3. Competitive Scenario

Chapter 3. Non-alcoholic Steatohepatitis Biomarkers Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Non-alcoholic Steatohepatitis Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
      • 3.3.2.1. Political Landscape
      • 3.3.2.2. Technological Landscape
      • 3.3.2.3. Economic Landscape

Chapter 4. Non-alcoholic Steatohepatitis Biomarkers Market: Type Estimates & Trend Analysis

  • 4.1. Type Segment Dashboard
  • 4.2. Non-alcoholic Steatohepatitis Biomarkers Market: Type Movement Analysis
  • 4.3. Global Non-alcoholic Steatohepatitis Biomarkers Market Size & Trend Analysis, By Type, 2018 to 2030 (USD Million)
  • 4.4. Serum Biomarkers
    • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5. Hepatic Fibrosis Biomarkers
    • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.6. Apoptosis Biomarkers
    • 4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.7. Oxidative Stress Biomarkers
    • 4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Non-alcoholic Steatohepatitis Biomarkers Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Segment Dashboard
  • 5.2. Non-alcoholic Steatohepatitis Biomarkers Market: End Use Movement Analysis
  • 5.3. Global Non-alcoholic Steatohepatitis Biomarkers Market Size & Trend Analysis, By End Use, 2018 to 2030 (USD Million)
  • 5.4. Pharma & CRO Industry
    • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5. Hospitals
    • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6. Diagnostic Labs
    • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.7. Academic Research Institutes
    • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Non-alcoholic Steatohepatitis Biomarkers Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Dashboard
  • 6.2. Regional Market Share Analysis, 2024 & 2030
  • 6.3. Non-alcoholic Steatohepatitis Biomarkers Market by Region: Key Takeaways
  • 6.4. North America
    • 6.4.1. U.S.
      • 6.4.1.1. Key Country Dynamics
      • 6.4.1.2. Regulatory Framework/ Reimbursement Structure
      • 6.4.1.3. Competitive Scenario
      • 6.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Canada
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.4.2.3. Competitive Scenario
      • 6.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Mexico
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.4.3.3. Competitive Scenario
      • 6.4.3.4. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. U.K.
      • 6.5.1.1. Key Country Dynamics
      • 6.5.1.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.1.3. Competitive Scenario
      • 6.5.1.4. U.K. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Germany
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.2.3. Competitive Scenario
      • 6.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.3. France
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.3.3. Competitive Scenario
      • 6.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Italy
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.4.3. Competitive Scenario
      • 6.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.5. Spain
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.5.3. Competitive Scenario
      • 6.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Denmark
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.6.3. Competitive Scenario
      • 6.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.7. Sweden
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.7.3. Competitive Scenario
      • 6.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.8. Norway
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework/ Reimbursement Structure
      • 6.5.8.3. Competitive Scenario
      • 6.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Japan
      • 6.6.1.1. Key Country Dynamics
      • 6.6.1.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.1.3. Competitive Scenario
      • 6.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.2. China
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.2.3. Competitive Scenario
      • 6.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.3. India
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.3.3. Competitive Scenario
      • 6.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.4. South Korea
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.4.3. Competitive Scenario
      • 6.6.4.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.5.3. Competitive Scenario
      • 6.6.5.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Thailand
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework/ Reimbursement Structure
      • 6.6.6.3. Competitive Scenario
      • 6.6.6.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.7.2.3. Competitive Scenario
      • 6.7.2.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.7.3.3. Competitive Scenario
      • 6.7.3.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework/ Reimbursement Structure
      • 6.8.2.3. Competitive Scenario
      • 6.8.2.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework/ Reimbursement Structure
      • 6.8.3.3. Competitive Scenario
      • 6.8.3.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework/ Reimbursement Structure
      • 6.8.4.3. Competitive Scenario
      • 6.8.4.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework/ Reimbursement Structure
      • 6.8.5.3. Competitive Scenario
      • 6.8.5.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/ Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key Company Heat Map Analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. GENFIT
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. Prometheus Laboratories
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. Siemens Healthineers AG
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. BioPredictive
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. Quest Diagnostics
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. AstraZeneca
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. Exalenz Bioscience Ltd (meridian bioscience)
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Labcorp
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. Pfizer Inc.
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Bristol-Myers Squibb Company
      • 7.4.10.1. Company Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Strategic Initiatives
Show more
Product Code: GVR-1-68038-518-2

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Non-alcoholic Steatohepatitis Biomarkers Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 5 Global Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 6 North America Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 8 North America Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 9 U.S. Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 10 U.S Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 11 Canada Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 12 Canada Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 13 Mexico Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 14 Mexico Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 15 Europe Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018 - 2030 (USD Million)
  • Table 16 Europe Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 17 Europe Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 18 U.K. Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 19 U.K. Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 20 Germany Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 21 Germany Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 22 France Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 23 France Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 24 Italy Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 25 Italy Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 26 Spain Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 27 Spain Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 28 Denmark Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 29 Denmark Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 30 Sweden Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 31 Sweden Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 32 Norway Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 33 Norway Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 37 Japan Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 38 Japan Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 39 China Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 40 China Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 41 India Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 42 India Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 43 South Korea Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 44 South Korea Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 45 Australia Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 46 Australia Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 47 Thailand Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 48 Thailand Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 49 Latin America Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018 - 2030 (USD Million)
  • Table 50 Latin America Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 51 Latin America Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 52 Brazil Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 53 Brazil Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 54 Argentina Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 55 Argentina Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market, by Country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 59 South Africa Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 60 South Africa Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 63 UAE Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 64 UAE Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Non-alcoholic Steatohepatitis Biomarkers Market, by Type, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Non-alcoholic Steatohepatitis Biomarkers Market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Data Triangulation Techniques
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Primary Interviews
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 QFD Modeling for Market Share Assessment
  • Fig. 8 Market Formulation & Validation
  • Fig. 9 Non-alcoholic Steatohepatitis Biomarkers Market: Market Outlook
  • Fig. 10 Non-alcoholic Steatohepatitis Biomarkers Competitive Insights
  • Fig. 11 Parent Market Outlook
  • Fig. 12 Related/Ancillary Market Outlook
  • Fig. 13 Penetration and Growth Prospect Mapping
  • Fig. 14 Industry Value Chain Analysis
  • Fig. 15 Non-alcoholic Steatohepatitis Biomarkers Market Driver Impact
  • Fig. 16 Non-alcoholic Steatohepatitis Biomarkers Market Restraint Impact
  • Fig. 17 Non-alcoholic Steatohepatitis Biomarkers Market Strategic Initiatives Analysis
  • Fig. 18 Non-alcoholic Steatohepatitis Biomarkers Market: Type Movement Analysis
  • Fig. 19 Non-alcoholic Steatohepatitis Biomarkers Market: Type Outlook and Key Takeaways
  • Fig. 20 Serum Biomarkers Market Estimates and Forecast, 2018 - 2030
  • Fig. 21 Hepatic Fibrosis Biomarkers Market Estimates and Forecast, 2018 - 2030
  • Fig. 22 Apoptosis Biomarkers Market Estimates and Forecast, 2018 - 2030
  • Fig. 23 Oxidative Stress Biomarkers Market Estimates and Forecast, 2018 - 2030
  • Fig. 24 Others Market Estimates and Forecast, 2018 - 2030
  • Fig. 25 Non-alcoholic Steatohepatitis Biomarkers Market: End Use Movement Analysis
  • Fig. 26 Non-alcoholic Steatohepatitis Biomarkers Market: End Use Outlook and Key Takeaways
  • Fig. 27 Pharma & CRO Industry Market, 2018-2030 (USD Million)
  • Fig. 28 Hospitals Market, 2018-2030 (USD Million)
  • Fig. 29 Diagnostic Labs Market, 2018-2030 (USD Million)
  • Fig. 30 Academic Research Institutes Market, 2018-2030 (USD Million)
  • Fig. 31 Global Non-alcoholic Steatohepatitis Biomarkers Market: Regional Movement Analysis
  • Fig. 32 Global Non-alcoholic Steatohepatitis Biomarkers Market: Regional Outlook and Key Takeaways
  • Fig. 33 North America Market Estimates and Forecasts, 2018 - 2030
  • Fig. 34 U. S. Market Estimates and Forecasts, 2018 - 2030
  • Fig. 35 Canada Market Estimates and Forecasts, 2018 - 2030
  • Fig. 36 Mexico Market Estimates and Forecasts, 2018 - 2030
  • Fig. 37 Europe Market Estimates and Forecasts, 2018 - 2030
  • Fig. 38 U. K. Market Estimates and Forecasts, 2018 - 2030
  • Fig. 39 Germany Market Estimates and Forecasts, 2018 - 2030
  • Fig. 40 France Market Estimates and Forecasts, 2018 - 2030
  • Fig. 41 Italy Market Estimates and Forecasts, 2018 - 2030
  • Fig. 42 Spain Market Estimates and Forecasts, 2018 - 2030
  • Fig. 43 Denmark Market Estimates and Forecasts, 2018 - 2030
  • Fig. 44 Sweden Market Estimates and Forecasts, 2018 - 2030
  • Fig. 45 Norway Market Estimates and Forecasts, 2018 - 2030
  • Fig. 46 Asia Pacific Market Estimates and Forecasts, 2018 - 2030
  • Fig. 47 Japan Market Estimates and Forecasts, 2018 - 2030
  • Fig. 48 China Market Estimates and Forecasts, 2018 - 2030
  • Fig. 49 India Market Estimates and Forecasts, 2018 - 2030
  • Fig. 50 South Korea Market Estimates and Forecasts, 2018 - 2030
  • Fig. 51 Australia Market Estimates and Forecasts, 2018 - 2030
  • Fig. 52 Thailand Market Estimates and Forecasts, 2018 - 2030
  • Fig. 53 Latin America Market Estimates and Forecasts, 2018 - 2030
  • Fig. 54 Brazil Market Estimates and Forecasts, 2018 - 2030
  • Fig. 55 Argentina Market Estimates and Forecasts, 2018 - 2030
  • Fig. 56 Middle East & Africa Market Estimates and Forecasts, 2018 - 2030
  • Fig. 57 South Africa Market Estimates and Forecasts, 2018 - 2030
  • Fig. 58 Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
  • Fig. 59 UAE Market Estimates and Forecasts, 2018 - 2030
  • Fig. 60 Kuwait Market Estimates and Forecasts, 2018 - 2030
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!